N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2

Journal of Medicinal Chemistry

Volumn 47, Issue 15, 2004, Pages 3710-3722

  Hardcastle, Ian R ^a   Arris, Christine E ^b   Bentley, Johanne ^b   Boyle, F Thomas ^d   Chen, Yuzhu ^b   Curtin, Nicola J ^b   Endicott, Jane A ^c   Gibson, Ashleigh E ^a   Golding, Bernard T ^a   Griffin, Roger J ^a   Jewsbury, Philip ^d   Menyerol, Jerome ^a   Mesguiche, Veronique ^a   Newell, David R ^b   Noble, Martin E M ^c   Pratt, David J ^c   Wang, Lan Zhen ^b   Whitfield, Hayley J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (6 CYCLOHEXYLMETHOXY 2 YLAMINO) N METHYLBENZENESULFONAMIDE; 4 (6 CYCLOHEXYLMETHOXY 9H PURIN 2 YLAMINO)BENZAMIDE; 6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; 6 CYCLOHEXYLMETHOXY 2 (4' HYDROXYANILINO)PURINE; 6 CYCLOHEXYLMETHOXY 2 (4' SULFAMOYLANILINO)PURINE; 6 O CYCLOHEXYLMETHYLGUANINE; 6 O CYCLOHEXYLMETHYLGUANINE DERIVATIVE; 6 O METHYLGUANINE; ADENOSINE TRIPHOSPHATE; AMIDE; CYCLIN A; CYCLIN A3; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 1 INHIBITOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; SULFONAMIDE; UNCLASSIFIED DRUG; CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLOHEXANE DERIVATIVE; DRUG DERIVATIVE; GUANINE; PURINE DERIVATIVE;

ARTICLE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HYDROGEN BOND; IC 50; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; STARFISH; SYNTHESIS;

ANIMALS; CDC2 PROTEIN KINASE; CDC2-CDC28 KINASES; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; CYCLOHEXANES; GUANINE; HUMANS; MODELS, MOLECULAR; PURINES; STARFISH; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3142580855     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0311442     Document Type: Article

References (55)

1. Norbury, C.; Nurse, P. A. Animal cell-cycles and their control. Annu. Rev. Biochem. 1992, 61, 441-470.
2. Morgan, D. O. Principles of CDK regulation. Nature 1995, 374, 131-134.
3. Sherr, C. J.; Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13, 1501-1512.
4. Hall, M.; Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. Adv. Cancer Res. 68, 1996, 67-108.
5. Stewart, Z. A.; Westfall, M. D.; Pietenpol, J. A. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 2003, 24, 139-145.
6. Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. Cyclin-dependent Kinase inhibitors: Useful targets in cell cycle regulation. J. Med. Chem. 2000, 43, 1-18.
7. Hardcastle, I. R.; Golding, B. T.; Griffin, R. J. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 325-348.
8. Knockaert, M.; Greegard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
9. Toogood, P. L. Progress toward the development of agents to modulate the cell cycle. Curr. Opin. Chem. Biol. 2002, 6, 472-478.
10. Akinaga, S.; Sugiyama, K.; Akiyama, T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? Anti-Cancer Drug Des. 2000, 15, 43-52.
11. de Azevedo, W. F.; Mueller-Dieckmann, H.-J.; Schulze-Gahmen, U.; Worland, P. J.; Sausville, E.; Kim, S.-H. Structural basis for the specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2735-2740.
12. Kim, K. S.; Sack, J. S.; Tokarski, J. S.; Qian, L. G.; Chao, S. T.; Leith, L.; Kelly, Y. F.; Misra, R. N.; Hunt, J. T.; Kimball, S. D.; Humphreys, W. G.; Wautlet, B. S.; Mulheron, J. G.; Webster, K. R. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: Synthesis and biological effects. J. Med. Chem. 2000, 43, 4126-4134.
13. Schoepfer, J.; Fretz, H.; Chaudhuri, B.; Muller, L.; Seeber, E.; Meijer, L.; Lozach, O.; Vangrevelinghe, E.; Furet, P. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J. Med. Chem. 2002, 45, 1741-1747.
14. Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G.. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281, 533-538.
15. Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 2003, in press.
16. Schow, S. R.; Mackman, R. L.; Blum, C. L.; Brooks, E.; Horsma, A. G.; Joly, A.; Kerwar, S. S.; Lee, G.; Schiffman, D.; Nelson, M. G.; Wang, X.; Wick, M. M.; Zhang, X.; Lum, R. T. Synthesis and activity of 2,6,9-trisubstituted purines. Bioorg. Med. Chem. Lett. 1997, 7, 2697-2702.
17. Imbach, P.; Capraro, H.-G.; Furet, P.; Mett, H.; Meyer, T.; Zimmermann, J. 2,6,9-Trisubstituted purines: Optimization towards highly potent and selective CDK1 inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 91-96.
18. Legraverend, M.; Tunnah, P.; Noble, M.; Ducrot, M.; Ludwig, O.; Grierson, D. S.; Leost, M.; Meijer, L.; Endicott, J. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 2000, 43, 1282-1292.
19. Dreyer, M. K.; Borcherding, D. R.; Dumont, J. A.; Peet, N. P.; Tsay, J. T.; Wright, P. S.; Bitonti, A. J.; Shen, J.; Kim, S.-H. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine derivative H717. J. Med. Chem. 2001, 44, 524-530.
20. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. 2001, 44, 4339-4358.
21. Dermatakis, A.; Luk, K.-C.; DePinto, W. Synthesis of potent oxindole CDK2 inhibitors. Bioorg. Med. Chem. Lett. 2003, 11, 1873-1881.
22. Andreani, A.; Cavalli, A.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Recanatini, M.; Garnier, M.; Meijer, L. Imidazo 2,1-b thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibition. Anti-Cancer Drug Des. 2000, 15, 447-452.
23. Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.; Ceballos-Picot, I.; Noble, M.; Endicott, J.; Vierfond, J.-M.; Meijer, L. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 2003, 46, 222-236.
24. Barvian, M.; Boschelli, D. H.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z. P.; Zhang, E. L. Pyrido 2,3-d pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2000, 43, 4606-4616.
25. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitors: X-ray crystallographic studies of 4-anilinoquinazolinones bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43, 133-138.
26. Sielecki, T. M.; Johnson, T. L.; Liu, J.; Muckelbauer, J. K.; Grafstrom, R. H.; Cox, S.; Boylan, J.; Burton, C. R.; Chen, H.; Smallwood, A.; Chang, C.-H.; Boisclair, M.; Benfield, P. A.; Trainor, G. L.; Seitz, S. P. Quinazolines as cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1157-1160.
27. Arris, C. E.; Boyle, F. T.; Calvert, A. H.; Curtin, N. J.; Endicott, J. A.; Garman, E. F.; Gibson, A. E.; Golding, B. T.; Grant, S.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Lawrie, A. M.; Newell, D. R.; Noble, M. E. M.; Sausville, E. A.; Schultz, R.; Yu, W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 2000, 43, 2797-2804.
28. Furet, P.; Meyer, T.; Strauss, A.; Raccuglia, S.; Rondeau, J. M. Structure-based design and protein X-ray analysis of a protein kinase inhibitor. Bioorg. Med. Chem. Lett. 2001, 11, 1157-1160.
29. Soni, R.; O'Reilly, T.; Furet, P.; Muller, L.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Fabbro, D.; Chaudhuri, B. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Inst. 2001, 93, 436-446.
30. Mesguiche, V.; Parsons, R. J.; Arris, C. E.; Bentley, J.; Boyle, F. T.; Curtin, N. J.; Davies, T. G.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Newell, D. R.; Noble, M. E. M.; Wang, L.; Hardcastle, I. R. 4-Alkoxy-2,6-diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13, 217-222.
31. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-based generation of a new class of potent CDK4 inhibitors: New de novo design strategy and library design. J. Med. Chem. 2001, 44, 4615-4627.
32. Yue, E. W.; Higley, C. A.; DiMeo, S. V.; Carini, D. J.; Nugiel, D. A.; Benware, C.; Benfield, P. A.; Burton, C. R.; Cox, S.; Grafstrom, R. H.; Sharp, D. M.; Sisk, L. M.; Boylan, J. F.; Muckelbauer, J. K.; Smallwood, A. M.; Chen, H. Y.; Chang, C. H.; Seitz, S. P.; Trainor, G. L. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3. J. Med. Chem. 2002, 45, 5233-5248.
33. Kim, K. S.; Kimball, S. D.; Misra, R. N.; Rawlins, D. B.; Hunt, J. T. et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities. J. Med. Chem. 2002, 45, 3905-3927.
34. Ortega, M. A.; Montoya, M. E.; Zarranz, B.; Jaso, A.; Aldana, I.; Leclerc, S.; Meijer, L.; Monge, A. Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 2002, 10, 2177-2184.
35. Brachwitz, K.; Voigt, B.; Meijer, L.; Lozach, O.; Schachtele, C.; Molnar, J.; Hilgeroth, A. Evaluation of the first cytostatically active 1-aza-9-oxofluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties. J. Med. Chem. 2003, 46, 876-879.
36. Hoessel, R.; LeClerc, S.; Endicott, J. A.; Nobel, M. E. N.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol. 1999, 1, 60-67.
37. Meijer, L.; Thunnissen, A.-M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L.-H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E.-M.; Kim, S.-H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3β and casein kinase I by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7, 51-63.
38. Soni, R.; Muller, L.; Furet, P.; Schoepfer, J.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Chaudhuri, B. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun. 2000, 275, 877-884.
39. Gussio, R. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anti-cancer Drug. Des. 2000, 15, 53-66.
40. Senderowicz, A. M.; Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 2000, 92, 376-387.
41. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. 2002, 8 (Suppl. 4), S32-S37.
42. 6-substituted guanine derivatives. J. Med. Chem. 2002, 45, 3381-3393.
43. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Tucker, J. A.; Wang, L.; Whitfield, H. J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 2002, 9, 745-749.
44. Yamamoto, H. Anomalous halogen to dimethylamino replacement with N,N-dimethylformamide catalyzed by ethylenediamine or 2-aminoethanol. Bull. Chem. Soc. Jpn. 1982, 55, 2685-2686.
45. Whitfield, H. J.; Griffin, R. J.; Hardcastle, I. R.; Henderson, A.; Menyerol, J.; Mesguiche, V.; Sayle, K. S.; Golding, B. T. J. Chem. Soc. Chem. Commun. 2003, 2802-2803.
46. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Baboul, A. G.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Bohnson, B.; Chen, W.; Wong, M. W.; Andres, J. L.; Gonzalez, C.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 1998, Version A.7. Gaussian, Inc., Pittsburgh, PA, 1998.
47. Sayle, K. L.; Bentley, J.; Boyle, F. T.; Calvert, A. H.; Cheng, Y.; Curtin, N. J., Endicott, J.; Golding, B. T.; Hardcastle, I. R.; Jewsbury, P.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Parsons, R. J.; Pratt, D. J.; Wang, L. Z.; Griffin, R. J. Structure-based design of 2-arylamino-4- cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin dependent kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13, 3079-3082.
48. Brown, N. R.; Noble, M. E.; Lawrie, A. M.; Morris, M. C.; Tunnah, P.; Divita, G.; Johnson, L. N.; Endicott, J. A. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 1999, 274, 8746-8756.
49. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 and ESF-EAMCB Newsletter on Protein Crystallography 1992, 26.
50. Evans, P. R. Data Reduction; Science and Engineering Research Council UK: Daresbury Laboratory, Warrington, 1993; pp 114-122.
51. CCP4 The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
52. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255.
53. Fletcher, D. A.; McMeeking, R. F.; Parkin, D. The United Kingdom Chemical Database Service. J. Chem. Inf Comput. Sci. 1996, 36, 746-749.
54. Jones, T. A.; Zou, J. Y.; Cowan, S. W. Kjeldgaard Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr., Sect. A: Found. Crystallogr. 1991, 47, 110-119.
55. Lamzin, V. S.; Wilson, K. S. Automated refinement of protein models. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1993, 49, 129-147.